Skip to main content

Model-Based Economic Evaluations of Interleukin Pathway Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Systematic Review of Model Structures, Assumptions, and Methodological Quality

In brief

No interleukin inhibitor sequence ranked best across 26 psoriasis cost studies

Across 26 economic evaluations, no drug or treatment sequence was consistently cost-effective across countries; results shifted with prices, comparators, thresholds, response rates, and sequencing assumptions. Most studies used trial evidence and formal sensitivity analyses, but few tested model logic and none systematically compared model structures, leaving rankings highly dependent on assumptions and local context.

Journal
Applied health economics and health policy (Q1)
Published
12 November 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Zhi Wang, Zixin Zhang, Pingyu Chen
PMID
43018877
DOI
10.1007/s40258-026-01087-7

Why clinicians should know about it

  • Picked for Dermatology (top studies of the week, 15 November 2026): Systematic review of targeted therapies for plaque psoriasis

Abstract

OBJECTIVES: To systematically review model-based economic evaluations of interleukin pathway inhibitors for moderate-to-severe plaque psoriasis, with a focus on model structures, key assumptions, parameter sources, economic conclusions, methodological rigor, and reporting completeness. METHODS: PubMed/MEDLINE, Embase, Web of Science, and the Cochrane Library were systematically searched from database inception through July 10, 2026, for full model-based economic evaluations in adults with moderate-to-severe plaque psoriasis in which at least one evaluated strategy included an interleukin (IL)-12/23, IL-17, or IL-23 inhibitor. Model architecture, health states, treatment sequences, sources of key parameters, and approaches to uncertainty were extracted a priori, and methodological features were compared through narrative synthesis. Methodological quality and reporting completeness were appraised using the Philips checklist and the Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022), respectively. Economic findings were synthesized separately for QALY-based cost-utility analyses and Psoriasis Area and Severity Index (PASI) response-based cost-effectiveness analyses. RESULTS: Twenty-six economic evaluations met the inclusion criteria. Thirteen used Markov or state-transition models, five used decision tree-Markov hybrids, two used decision trees, four used cost-effectiveness models without a stated formal architecture, and two used patient-level or other simulation models; 14 explicitly modeled multi-line treatment sequences. Twenty-four evaluations used evidence from randomized controlled trials as effectiveness inputs, and 19 incorporated network meta-analysis or mixed-treatment comparison estimates. Twenty-one conducted formal deterministic sensitivity analyses, with one additional evaluation reporting a limited one-way analysis; 20 conducted probabilistic sensitivity analyses, and 16 reported cost-effectiveness acceptability curves. Only four studies explicitly described tests of model logic, and none systematically compared alternative model structures; subsequent-line effectiveness and patient heterogeneity were also inconsistently addressed. Economically, 16 evaluations were QALY-based cost-utility analyses and 10 were PASI response-based cost-effectiveness analyses. No drug or treatment sequence was consistently optimal across countries; conclusions varied primarily with comparator choice, drug prices, willingness-to-pay thresholds, short-term response rates, and sequencing assumptions. CONCLUSIONS: Existing models increasingly represent long-term, multi-line treatment pathways, but their treatment of prior treatment history, subsequent-line effectiveness and discontinuation, structural uncertainty, and model validation remains inadequate. Future evaluations should incorporate previous biologic exposure, long-term drug survival, and locally relevant utility and resource-use data, and should explicitly test important alternative model structures. Current economic conclusions are strongly model- and context-dependent; cross-country rankings should not be inferred without accounting for specific prices, thresholds, and treatment sequences. PROSPERO Registration: CRD420261413139.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.